Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Clinical characteristics, treatment strategies, and response patterns in evans syndrome: Initial analysis from the spanish resti cohort

Maria Eva Mingot, Elena Sebastián Pérez, Javier Bañon Soria et al. Nov 03, 2025 pp. 1263-1263 10.1182/blood-2025-1263

Abstract Introduction: Evans syndrome (ES) is a rare, heterogeneous autoimmune disorder characterized by the simultaneous or sequential occu...

Golidocitinib, a selective JAK1 kinase inhibitor, in treatment of late thrombocytopenia after CAR-T cell therapy: Case report

Qichun Cai, Jianing Li, Jiasheng Li et al. Nov 03, 2025 pp. 7688-7688 10.1182/blood-2025-7688

Abstract BackgroundDespite its remarkable success, CAR-T therapy is accompanied by common adverse events, including cytokine release syndrom...

Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium

Andrew Portuguese, James Davis, Shahzad Raza et al. Nov 03, 2025 pp. 136-136 10.1182/blood-2025-136

Abstract Introduction: Elranatamab, a BCMA-CD3 bispecific antibody, has shown efficacy in relapsed multiple myeloma (MM), but real-world dat...

Long-term outcome and risk factors for relapse in pediatric warm autoimmune hemolytic anemia.

Diane Roze, Nathalie Garnier, Marlène Pasquet et al. Nov 03, 2025 pp. 4657-4657 10.1182/blood-2025-4657

Abstract Warm-antibody autoimmune hemolytic anemia (wAIHA) in children is a rare condition with limited data to predict outcomes or optimize...

Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study

Behnam Noorani, Leonid Gibiansky, Kinjal Sanghavi et al. Nov 03, 2025 pp. 1820-1820 10.1182/blood-2025-1820

Abstract Introduction: Epcoritamab is a subcutaneous CD3xCD20 bispecific T-cell engager approved for treating relapsed or refractory (R/R) d...

Development and validation of the predictive aplastic score system (PASS): A simplified tool to diagnose acquired aplastic anemia in adults

Gabriel Aleixo, Heejin Cheon, Jiayin Zheng et al. Nov 03, 2025 pp. 1418-1418 10.1182/blood-2025-1418

Abstract Acquired aplastic anemia (AA) is an immune-mediated bone marrow failure characterized by pancytopenia and a hypocellular marrow, re...

The relationship between neutrophil-to-lymphocyte ratio and mid-term evaluation in patients with gastrointestinal Diffuse large B-cell lymphoma

Weiran Li, Sijia Shang, Guowen Zhao et al. Nov 03, 2025 pp. 7198-7198 10.1182/blood-2025-7198

Abstract Background: Diffuse large B - cell lymphoma (DLBCL) is the most common subtype of non - Hodgkin lymphoma. Approximately 30% - 40% o...

Lactate promotes DLBCL progression via NAT10/ldha axis and immune suppression

Xiaodong Guo, Wancheng Liu, Daoxin Ma Nov 03, 2025 pp. 3562-3562 10.1182/blood-2025-3562

Abstract Introduction: Lactate, a metabolic byproduct, can induce protein lactylation that plays a key role in protein stability. However, t...

Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination

Howard Oster, Sandra Huber, Jacqueline Ferrari et al. Nov 03, 2025 pp. 5632-5632 10.1182/blood-2025-5632

Abstract Background: Myelodysplastic syndromes (MDS) are often preceded by preMDS states, idiopathic cytopenia of undetermined significance...

Advancing sickle cell disease diagnosis in low-resource settings using Gazelle™, a paper-based microchip electrophoresis platform

Arwa Fraiwan, Jibril Binta, Bernard Ebruke et al. Nov 03, 2025 pp. 2936-2936 10.1182/blood-2025-2936

Abstract Sickle Cell Disease (SCD), an inherited hemoglobinopathy, disproportionately affects people from the African subcontinent extensive...

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft-versus-host disease following umbilical cord blood transplantation

Mika Kuno, Hisashi Yamamoto, Otoya Watanabe et al. Nov 03, 2025 pp. 7757-7757 10.1182/blood-2025-7757

Abstract Background: Umbilical cord blood transplantation (UCBT) is associated with a slightly lower incidence and sever...

Circulating cell-free BRAFV600E as a biomarker in patients with erdheim-chester disease

Long Chang, Wei-tong Liu, He Lin et al. Nov 03, 2025 pp. 2038-2038 10.1182/blood-2025-2038

Abstract Background and aims: Erdheim-Chester disease (ECD) is a rare, heterogeneous histiocytic disease with recurrent MAPK pathway mutatio...

Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study

Zachary Crees, Michael Rettig, Peter Ruminski et al. Nov 03, 2025 pp. 5956-5956 10.1182/blood-2025-5956

Abstract Autologous hematopoietic stem cell (HSC) based gene therapy for sickle cell disease (SCD) requires mobilizing sufficient peripheral...

A unified clinical algorithm for the diagnosis and management of platelet transfusion refractoriness: A systematic synthesis and proposed framework

Akshit Chitkara, FNU Anamika, Sai Abhishek Narra et al. Nov 03, 2025 pp. 6693-6693 10.1182/blood-2025-6693

Abstract Background: Platelet transfusion refractoriness (PTR), or inability to achieve an acceptable rise in platelet c...

Ectopic BCL11B disrupts the activity of early hematopoietic transcription factors to skew lineage commitment

Lindsey Montefiori, Huimei Wei, Wojciech Rosikiewicz et al. Nov 03, 2025 pp. 3230-3230 10.1182/blood-2025-3230

Abstract Enhancer hijacking events that aberrantly activate the T-lineage transcription factor (TF) gene, BCL11B, define a subtype of lineag...

Etiology of anemia in a murine model of myelodysplastic syndrome

Kathleen McGrath, Allison Li, Michael Becker et al. Nov 03, 2025 pp. 6713-6713 10.1182/blood-2025-6713

Abstract MDS are clonal stem cell disorders characterized by peripheral cytopenias, particularly macrocytic anemia, which is often refractor...

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Anand Patel, Adam Duvall, Caner Saygin et al. Nov 03, 2025 pp. 441-441 10.1182/blood-2025-441

Abstract Introduction: Amongst patients (pts) ≥ 50 years old diagnosed with B-ALL, half have Ph+ ALL. Achieving a BCR::ABL1 qRT-PCR of &...

Immune-based risk score derived from bulk and single-cell transcriptomics enhances prognostic stratification in MDS

Nicolas Sompairac, Ziying Zhang, Rosa Andres Ejarque et al. Nov 03, 2025 pp. 115-115 10.1182/blood-2025-115

Abstract Background Bulk RNA sequencing is a powerful and cost-effective high-throughput technology that provides comprehensive insights int...

Preoperative platelet transfusion in cancer surgery: Outcomes across and above guideline thresholds

Fatma Yilmaz, Jake Fanizza, Salih Akgun et al. Nov 03, 2025 pp. 546-546 10.1182/blood-2025-546

Abstract Background: Thrombocytopenia is common in patients with malignancy and frequently encountered prior to surgery. Perioperative guide...

Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data

Sneha Rathi, Vanessa Schmitt, Heiko Babel et al. Nov 03, 2025 pp. 2266-2266 10.1182/blood-2025-2266

Abstract Introduction Etentamig (ABBV-383) is a differentiated B-cell maturation antigen (BCMA) x CD3 bispecific antibody (fully humanized I...

Outcomes of elderly patients with newly diagnosed multiple myeloma (NDMM): A retrospective comparison of daratumumab-based induction versus autologous stem cell transplant (autoSCT)

Kwan-Keat Ang, Arvind Suresh, Meryl Colton et al. Nov 03, 2025 pp. 6346-6346 10.1182/blood-2025-6346

Abstract Introduction: AutoSCT is often considered for fit patients up to the age of 75. However, the MAIA trial showed that transplant-inel...

Therapeutic targeting of focal adhesion kinase (FAK) modulates oncogenic and immune pathways in myeloid progenitor cells expressing oncogenic Janus kinase 2-V617F.

Subbaiah Chary Nimmagadda, Yifan Zhi, Matti Lawrenz et al. Nov 03, 2025 pp. 3757-3757 10.1182/blood-2025-3757

Abstract Introduction: Myeloproliferative neoplasms (MPNs) are clonal blood cancers marked by excessive production of mature myeloid cells. T...

Association of infection frequency and incident clonal hematopoiesis

Ajibike Lapite, Vernon Burk, James DeCuir et al. Nov 03, 2025 pp. 4942-4942 10.1182/blood-2025-4942

Abstract Background: Clonal hematopoiesis (CH) is an age-related phenomenon in which hematopoietic stem cells acquire somatic mutations that...

Inflammatory and oxidative stress biomarkers associated with cognitive function in patients with Hodgkin lymphoma treated with chemotherapy

Tianming Zhao, Hongying Sun, Bryan Thompson et al. Nov 03, 2025 pp. 3619-3619 10.1182/blood-2025-3619

Abstract Background: Cancer-related cognitive impairment (CRCI) is a common and clinically significant issue among cancer patients, negativel...

Real-world evidence of improved survival with pola-based regimen in newly diagnosed DLBCL patients with extranodal involvement

Xi Chen, Kexing Ren, Ming Jiang et al. Nov 03, 2025 pp. 5472-5472 10.1182/blood-2025-5472

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with extranodal (EN) involvement in nearly 50% of new...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page